青年研究员
Email: zhenqiuliu@fudan.edu.cn
工作经历
2010.09 - 2015.06，安徽医科大学，预防医学专业，本科
2015.09 - 2018.06，复旦大学公共卫生学院，流行病与卫生统计学专业，硕士
2018.09 - 2021.06，复旦大学生命科学学院，遗传学专业，博士
2021.06 - 2023.12，复旦大学人类表型组研究院，博士后
2024.01至今，复旦大学人类表型组研究院，青年研究员
研究方向
慢性肝脏疾病（脂肪肝、病毒性肝炎、肝癌）分子/遗传流行病学
招生专业
流行病学、医学统计学、生物信息学、分子生物学
获奖情况
2018、2021年，上海市优秀毕业生
2020年，复旦大学学术之星
2021年，第六届“博新计划”
2021年，上海市“超级博士后”
2024年，上海市青年科技“启明星”（A类）
代表论文
1. Liu Z#, Jiang Y#, Yuan H, et al. The trends in incidence of primary liver cancer caused by specific etiologies: results from the Global Burden of Disease Study 2016 and implications for liver cancer prevention. J Hepatol. 2019; 70(4): 674–683.
2. Liu Z#, Yang Q#, Cai N, et al. Enigmatic Differences by Sex in Cancer Incidence: Evidence from Childhood Cancers. Am J Epidemiol. 2019; 188 (6): 1130-1135.
3. Liu Z, Lin C, Mu L, et al. The disparities in gastrointestinal cancer incidence among Chinese populations in Shanghai compared with Chinese immigrants and indigenous non−Hispanic white populations in Los Angeles, USA. Int J Cancer. 2020; 146(2): 329-340.
4. Liu Z#, Mao X#, Yu K, et al. Prevalence of HCV resistance-associated substitutions among treatment-failure patients receiving direct-acting antiviral agents. J Viral Hepat. 2020; 27(6): 585-592.
5. Liu Z#, Mao X#, Wu J#, et al. World-wide prevalence of substitutions in HCV genome associated with resistance to direct-acting antiviral agents. Clin Gastroenterol Hepatol. 2021; 19 (9): 1906-1914.
6. Liu Z#, Xu K#, Jiang Y, et al. Global trend of aetiology-based primary liver cancer incidence from 1990 to 2030: a modelling study. Int J Epidemiol. 2021;50(1): 128-142.
7. Liu Z#, Suo C#, Shi O, et al. The health impact of MAFLD, a novel disease cluster of NAFLD, is amplified by the integrated effect of fatty liver disease-related genetic variants. Clin Gastroenterol Hepatol. 2022; 20(4): e855-e875.
8. Liu Z#, Lin C#, Suo C#, et al. Metabolic dysfunction-associated fatty liver disease and the risk of 24 specific cancers. Metabolism. 2022; 127:154955.
9. Liu Z, Suo C, Fan H, et al. Dissecting causal relationships between nonalcoholic fatty liver disease proxied by chronically elevated alanine transaminase levels and 34 extrahepatic diseases. Metabolism. 2022; 135:155270.
10. Liu Z#, Song C#, Suo C, et al. Alcohol consumption and hepatocellular carcinoma: novel insights from prospective cohort study and nonlinear Mendelian randomization analysis. BMC Med. 2022; 20:413.
11. Liu Z#, Lin C#, Mao X#, et al. Changing prevalence of chronic hepatitis B virus infection in China between 1973 and 2021: a systematic literature review and meta-analysis of 3740 studies and 231 million people. Gut. 2023, 72(12):2354-2363.
12. Guo C#, Liu Z#, Fan H, et al. Machine learning-based plasma metabolomic profiles for predicting long-term complications of cirrhosis. Hepatology, 2024. doi: 10.1097/HEP.0000000000000879.
13. Yuan H#, Liu Z#, Chen M, et al. Protein truncating variants in mitochondrial-related nuclear genes and the risk of chronic liver disease. BMC Med. 2024; 22: 239.
14. Liu Z#, Yuan H#, Wang Y#, et al. Proteogenomic analysis identifies a causal association between plasma apolipoprotein B levels and liver cancer risk. J Proteome Res. 2024;23(9):4055-4066.
15. Guo C#, Liu Z#, Fan H, et al. Nonlinear relationships of circulating polyunsaturated fatty acids with the complications of liver cirrhosis: A prospective, longitudinal cohort study. Clinical Nutrition. 2024; 43(9):2083-2091.
16. Liu Z, Yuan H, Suo C, et al. Point-based risk score for the risk stratification and prediction of hepatocellular carcinoma: a population-based random survival forest modeling study. eClinicalMedicine. 2024; 75:102796.
17. Liu Z#, Chen X#, Yuan H, et al. Dissecting the Shared Genetic Architecture Between Nonalcoholic Fatty Liver Disease and Type 2 Diabetes. Hum Mol Genet. 2024.
